This is an old revision of this page, as edited by Jmax- (talk | contribs) at 14:03, 3 January 2007 (Reverted edits by Agjchs to last version by Jni). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:03, 3 January 2007 by Jmax- (talk | contribs) (Reverted edits by Agjchs to last version by Jni)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the CNS by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal via the norepinephrine transporter. Virtually, they do not act at other monoamine transporters.
List of NRIs
- Atomoxetine (Strattera)
- Reboxetine (Edronax)
- Viloxazine (Vivalan)
- Maprotiline (Ludiomil)
Strattera is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD. Off-label uses include the treatment of depression and anxiety.
Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |